Carvipress25 mg

Carvipress 25 mg is indicated for the treatment of mild, moderate or severe heart failure of ischemic or cardiomyopathic origin, in conjunction with digitalis, diuretics and ACE inhibitor, to reduce the progression of disease as evidenced by cardiovascular death, cardiovascular hospitalization, or the need ... Read moreCarvipress 25 mg is indicated for the treatment of mild, moderate or severe heart failure of ischemic or cardiomyopathic origin, in conjunction with digitalis, diuretics and ACE inhibitor, to reduce the progression of disease as evidenced by cardiovascular death, cardiovascular hospitalization, or the need to adjust other heart failure medications. Carvipress 25 mg may be used in patients unable to tolerate an ACE inhibitor. Carvipress 25 mg may be used in patients who are not receiving digitalis, hydralazine or nitrate therapy.

Alpha adrenoceptor blocking drugs, Beta-adrenoceptor blocking drugs, Beta-blockers

Carvipress 25 mg is a non selective β-adrenergic blocking agent which causes vasodilation by blocking the activity α-1 receptors. It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation.

Hypertension: Initially 12.5 mg once daily, increased after 2 days to usual dose of 25 mg once daily; if necessary may be further increased at intervals of at least 2 weeks to max.50 mg daily in single or divided doses; Elderly: Initial dose of 12.5 mg daily may provide satisfactory control. Angina: Initially 12.5 mg twice daily, increased after 2 days to 25 mg twice daily.Heart failure (under special supervision): Initially 3.125 mg twice daily (with food), dose increased at intervals of at least 2 weeks to 6.25 mg twice daily, then to 12.5 mg twice daily, then to 25 mg twice daily, increase to highest dose tolerated, maximum 25 mg twice daily in patients with severe heart failure or body-weight less than 85 kg and 50 mg twice daily in patients over 85 kg.

In hypertension: initially, 12.5 mg once daily, increased after 2 days to the usual dose of 25 mg once daily; if necessary the dose may be further increased at intervals of at least 2 weeks to maximum 50 mg daily in single or divided doses. In elderly patients, the initial dose of 12.5 mg daily may provide satisfactory control.In angina pectoris: the recommended dose for initiation of therapy is 12.5 mg twice daily for the first 2 days. Thereafter, the recommended dosage is 25 mg twice daily. For elderly patients, the maximum daily dose is 50 mg daily in divided doses.In heart failure: initially, 3.125 mg twice daily (with food) may be given, the dose may be increased at intervals of at least 2 weeks to 6.25 mg twice daily, then to 12.5 mg twice daily, then to 25 mg twice daily. The dose may be increased to the highest dose tolerated, maximum 25 mg twice daily in patients less than 85 kg body-weight and 50 mg twice daily in patients over 85 kg.

Digoxin: In normal healthy volunteers a single dose of Carvipress 25 mg taken together with a single dose of digoxin resulted in significantly increased levels of digoxin 24 hours later. Patients with congestive heart failure stabilized on digoxin have been given Carvipress 25 mg concomitantly without any adverse effects. Increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing the dose of Carvipress 25 mg.Rifampin: Pretreatment with rifampin resulted in a 60% decrease in Cmax and AUC.Warfarin: Carvipress 25 mg did not alter the in vitro plasma protein binding of warfarin.Clonidine: β-receptor antagonists potentiate the pressor reaction which may follow the sudden withdrawal of treatment with clonidine although, in theory, the a-blocking action of Carvipress 25 mg should modify the pressure rise.

Carvipress 25 mg is contraindicated in patients with decompensated heart failure requiring intravenous inotropic therapy, bronchial asthma or related bronchospastic conditions, second or third-degree AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia.

Postural hypotension, dizziness, headache, fatigue, gastro-intestinal disturbances, bradycardia; occasionally diminished peripheral circulation, peripheral oedema and painful extremities, dry mouth, dry eyes, eye irritation or disturbed vision, impotence, disturbances of micturition, influenza-like symptoms, rarely angina, AV block, exacerbation of intermittent claudication or Raynaud's phenomenon, allergic skin reactions, exacerbation of psoriasis, nasal stuffiness, wheezing, depressed mood, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, leukopenia are also reported.

Carvipress 25 mg should not be used during pregnancy as no studies have been performed in this group. Carvipress 25 mg and its metabolites are excreted in breast milk. Therefore, breastfeeding is not recommended during administration of Carvipress 25 mg.

Take caution in hepatic impairment and in heart failure monitor clinical status for 2-3 hours after initiation and after increasing each dose. Before increasing dose ensure that the renal function and heart failure are not deteriorating

Symptoms: Severe hypotension, bradycardia, heart failure, cardiogenic shock and cardiac arrest. Resp problems, bronchospasms, vomiting, lapses of consciousness and generalised seizures. Management: Symptomatic and supportive treatment. Consider use of atropine for excessive bradycardia, IV glucagon or sympathomimetics to support ventricular function. Consider using norfenephrine or noradrenaline if vasodilation dominates the intoxication profile and IV inj of diazepam or clonazepam for seizures.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

The safety and efficacy of Carvipress 25 mg in paediatric patients have not been established.

Alpha adrenoceptor blocking drugs, Beta-adrenoceptor blocking drugs, Beta-blockers

Carvipress 25 mg is a cardiovascular drug whose main pharmacological action is non-selective antagonism of β-adrenergic receptors but which also possesses appreciable a-adrenergic antagonistic activity. It also has antiproliferative properties and is a scavenger of reactive free oxidant radicals. It is used in the treatment of hypertension, angina pectoris and congestive heart failure.

Carvipress 25 mg should not be used during breast-feeding, since no studies have been performed in lactating women and animal studies have shown that Carvipress 25 mg is excreted in breast milk. Safety and efficacy in children have not been established with Carvipress 25 mg. Carvipress 25 mg should not be used during pregnancy as no studies have been performed in this group. Animal studies have shown that Carvipress 25 mg crosses the placental barrier. No information is available on the safety and efficacy of Carvipress 25 mg use in neonates.